This phase 2/3 , randomized , placebo-controlled , observer-blinded study assessed the immunogenicity , reactogenicity , and safety of an inactivated , split-virion H5N1 influenza vaccine ( A/Indonesia/5 / 2005 ) in children aged 6 months through 17 years .